Standards For Molecular Imaging Agents Can Vary, Panel Tells FDA
Executive Summary
The evidence needed to show efficacy and utility of a molecular imaging agent depends on what is being scanned and what claim is being sought, FDA's Peripheral and Central Nervous System Drugs Advisory Committee advised the agency Aug. 11